Search results for query: *

Yes, of course, but not without Apollo 1. It happens.

I would highly advise you to take your vitamin D3 5000 iu even if it (and I doubt) increases tinnitus. D3 is a great immunity booster from everything out there.

Good point. There is a signal, meaning it works, yet, it is still unclear to understand what it is we are missing with FX-322. I guess one could say that the cochlea is the 'final frontier' of medicine. It's a difficult journey to the answer, but a step forward has been made. There is now hope...

47% had statistically significant improvement after seven months of FX-322 treatment. Not bad!

FX-322 is not getting a fair trial and FREQ knows it.

If you're speaking of both ears being the price to pay, then the self-chosen sounds of silence would wreak one into eventual severe depression with no recourse.

There are millions of people who have sensorineural hearing loss around the world who are holding out their only hope for Frequency Therapeutics to find a breakthrough on a signal that FX-322 has already provided. It is a painfully long process in between clinical trials and data readouts - in...

Frequency Therapeutics is a good, sound company with strong management and expertise in the field of progenitor cellular science that happens to have credence in restoring sensorineural hearing loss one day. Restoring hearing loss is like the final frontier of potential medical breakthroughs and...

It appears there is an ongoing lawsuit from a group of investors against Frequency Therapeutics. The investigation concerns whether Frequency Therapeutics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You may have misunderstood me pertaining to audiologists. There is currently an unknown reason for the bias that occurred in Phase 2a. As well, it's well known that any success with FX-322 could effect the hearing aid industry in a negative way - and audiologists are basically the middle-man in...

The science behind PCA is groundbreaking medical technology and FX-322 has been proven to increase audibility and clarity in trail participants with mild-moderate sensorineural hearing loss. In regard to Phase 2a, there was a bias within the trial design and it wouldn't surprise me if not the...

90 days may be enough time to develop hearing function within the womb prior to birth, but out here in the world to regenerate hearing in an adult without a doubt takes a little longer - it is complex but we are getting there. Wait for the full readout, I am very confident there will be good...

Frequency Therapeutics will eventually zero in on successfully treating sensorineural hearing loss, it is only a matter of time. It is back to the drawing board to unlock the answers we need, the signal is there.

A clever manipulative move from insiders, seems like they sell every week to entice speculative buyers leading up to the 90-day. Great for swing traders and those with sensorineural hearing loss - no need to FREQ out, it's good news!

Looking forward to Phase 5... in my ENT Physician's office, both ears!

The coming decade, I believe, will grant us one giant step forward in PCA regenerative medicine, whereby such maladies like tinnitus and hearing loss will eventually become annoyances easily treated by an ENT physician. I wouldn't concern yourself with a fear of a return to past audible...

Gotta love it... the ears of investors and traders are experiencing newfound clarity on simply the news of FX-322 and its potential - something nearly everyone on this forum already knows. Word has gotten out that Frequency Therapeutics has a jewel in the making and are finally receiving...

At least in the United States, pharmaceutical companies have little influence on the private health insurance industry in relation to what they specifically cover. One way or another, the patient will pay whether directly or through high insurance premiums. I'm speculating that the cost for...

The Promising Pathways Act is for drugs intended to treat, prevent, or diagnose serious or life-threatening diseases or conditions for patients who are battling critical conditions. These individuals would gladly trade their condition for sensorineural hearing loss if given a choice. I am a...

It's questionable whether 'provisional approval' would be granted based on considerable efficacy over current alternatives, which, in my opinion, it would not unfortunately.

Keep in mind what FX-322, on record, is designated to treat, if proven effective in the current phase - Mild to Moderate Sensorineural Hearing Loss. Realistically, provisional approval of this potential miracle drug is unlikely to occur due to other resources available i.e. hearing aids...

It's A Wonderful Life... as George Bailey was just as happy at the end of this Christmas Classic movie. It is all in the hands of those brilliant minds in Woburn, MA. I hope so much your prayers and those of others come true!

This is very good news! Frequency Therapeutics has yet, of course, to turn a profit but are investing in a highly intellectual individual to lead the way through the final phase and onto the market - very promising, to say the least.

Good point, but I would think that Frequency Therapeutics in all likelihood would have correspondence only with the ENT physicians of those patients, not with the patients themselves. Physicians would provide a much more thorough, professional analysis that answers the questions that the...

It is interesting that FX-322 clinical trial Phase 1b-112 and 113, which adds a much broader range of individuals to the study, is being rather condensed in an expeditious manner. Conceivably in doing so, it lessens the appeal or need of continuing with a lengthy, full-blown Phase III clinical...

I don't believe I said that veterans would be the only ones eligible for compassionate use, but the first to receive such, if at all. The U.S. military is huge as you may know and they have longed for ear protection for its members, and its relationship with Frequency Therapeutics has been...

The Food and Drug Administration has literally hundreds of reviews going on with various pharmaceuticals, medical devices, cosmetics, food products, and more. Envision the FDA as being the planet Earth, Frequency Therapeutics would be a star, not the moon. This is why 2023 doesn't sound too...

From what I understand, many participants in the clinical trials have been United States combat veterans in the San Antonia, Texas area among other locations throughout the country. When we speak of compassionate use one can rest assured that U.S. military veterans up to age 85 will be the...

One does not need to have insider information to know that FX-322 will not be available in 2021. Frequency Therapeutics will present an end of study analytical report of Phase 2a in June, 2021. This report will also be presented to the FDA for review - just imagine the length of time that will...

Great news from Frequency Therapeutics today as they are wasting no time to accelerate the FX-322 program. A very positive indication of clinical design to potentially broaden the market and further define the target population.

You raise some very good points on the potential accessibility of FX-322 after Phase 2a. As a counterpoint, the primary issue would be the findings of the study from only 95 participants. Given the limited variability of audiogram scores after treatment, the cost factors for the procedure...

Generally speaking, I don't think compassionate use of FX-322 is going to occur, for the most part, and should not be expected. Frequency Therapeutics are focused, I believe, on the successful completion of the clinical trial process before anyone has access other than trial participants...

Well said. It is one thing to go to the same audiologist over time and improve "your skills" at word recognition scores and make light of 10 dB alterations and another to immerse yourself in a Frequency Therapeutics 21-month clinical trial. For the closest to true accuracy, I'd place my bet...

Trading vibes on investments in Frequency Therapeutics may be boring to some but in all practicality it has everything to do with the health of the company. A viable product will only come about through investments in on-going research including the payroll of those doing the research. It is a...

Your argument is plausible in a theoretical sense of why the FDA requires clinical trials and why they take so long - because there are questions out there such as yours and rightfully so. You mentioned that Frequency Therapeutics have based their findings on assumptions rather than evidence...

Your assumption pertaining to repeat dosages not improving the lower frequencies is valid in my opinion, however, it is known that an improvement on delivery of FX-322 throughout the cochlea is on the 'front burner' and will be forth-coming. In the early study conducted on mice total hearing...

The Phase III clinical trial of FX-322 will be somewhat more time-consuming it will seem than previous segments of the process. Despite the results of Phase 2a, the third and final phase will involve many more participants across the United States, perhaps several hundred. These potential...

Frequency Therapeutics as we all know is a Bio-Tech research company based in the United States and they are well aware of how the health insurance industry in the U.S. can be quite selective as to what they cover and what they will not cover. I must differ with you in regard with this being a...

One thing for sure in the United States is that military and police recruits and those ending their careers or returning from the battlefield will assuredly receive complimentary FX-322 if their audiogram indicates hearing loss. Private insurance companies will most likely offer plans that...

Keep in mind, a deaf mouse was cured with total hearing restored all with FX-322!

It is my understanding that FX-322 is made of two molecular agents, one to activate and one to instigate growth - it has been proven this is the case. Given the shape of the cochlea, I am still pondering the thought of how FX-322 will travel to the apex (250 Hz) through multiple dosing and if...

Concerning the systemic drug delivery that was utilized in Phase 2a, are you inferring that the first dose of FX-322 administered will cover the frequencies that are expected (say, from 20 kHz to 8 kHz) and a second dose will bypass these frequencies (if PCA has occurred) and commence activating...

If your tinnitus is caused by noise-induced hearing loss it would have to be derived from those high frequencies from 8-20 kHz I would think. IF that is the case, FX-322 would likely be of substantial benefit. An extended audiogram would indicate this prognosis. It's a question with no answer...

That my Tinnitus was most likely the cause of sensorineural hearing loss and that in order to defeat Tinnitus, we need to return those X's and O's on my audiogram to within normal range. The truth about ongoing development in this area that could make it happen - in the meantime, find ways to...

I would not be surprised that by 2025, in the aftermath of the release of FX-322, a year or two prior, the delivery will be successfully modified to treat all frequencies, thereby, finally curing sensorineural hearing loss and tinnitus that is caused by this type of hearing loss. What a...

FX-322 was proven to be safe during the initial trial so any petitions or requests for additional trials from anyone other than a group of medical professionals in the field (and even these cherished folks) will fall on deaf ears, pardon the jocular pun. Hearing aid companies AND audiologists...

Frequency Therapeutics has a strategic partnership with Astellas in the development and deployment of FX-322 onto world markets. You can rest assured that all the specifics that go into marketing and accessibility of this drug to millions of individuals are concurrently being worked out. The...

The comparison of the advent of LASIK and the eye care industry at the time with what we are likely to see with the potential success of FX-322 and the hearing aid industry, I believe, is limited to similarities in economics only and it stops there. Hearing loss and tinnitus, unlike poor...

It is interesting that you point out the "hearing sector". The hearing aid industry throughout the world is huge and has enjoyed for many years as an industry monopoly on providing 'patients' with an answer to getting on with their lives. The Audiologist is the middle man or woman you go to in...

The article implies not so much a skeptical perception of the early trial involving 23 participants, but one of a guarded and reserve observation. It takes into account deviations of the variance involving audiograms that could, perhaps, be plausible in early clinical trials. Conquering...

I totally agree. At the risk of advancing to an optimistic plateau on the thought of FX-322 being the potential cure, yes cure, I believe we have finally reached 'the light at the end of the tunnel' whereas through modifications along the way we may be witnessing the beginning of the end of...

In all probability, sensorineural noise-induced hearing loss treatment with FX-322 in the United States would not be covered by most individuals insurance plans with their employers or Medicare for that matter. There is a huge market out there for FX-322 and insurance companies will most likely...

Zero. FX-322 is simply two molecules turning on a switch to activate an otherwise natural process. This has occurred already with all of us when we were in the womb. If you believe Internet drama, look no further than Aspartame, the virtually harmless sweetener in Diet Coke for nearly 40...

I thought I'd share this interesting thought on the meaning of the numerical 322 supposedly from biblical times and being used today by Frequency Therapeutics on the hypothesis of FX-322 potentially being the Godsend for eradicating not only sensorineural hearing loss, yet an array of differing...

Dosing for four straight weeks followed by an observation of 210 days (seven months).

FREQ currently has a Quantitative Rating of 4 - BUY! Interestingly, they announced $42m in private placements by a group of investors in late July, approximately 9 months after the start of Phase 2a. The additional revenue is expected to finance their next clinical trial phase for FX-322. It...

It is my understanding that September 30, 2020 is the estimated study completion date and primary completion date, whereas the last participant in the clinical trial is examined or treated before the data compilation begins. "The date on which the last participant in a clinical study was...

Not true! The arrival of FX-332 onto the market is nearly right on course as planned despite the economic downturn during 2020. It will not be harder to get FX-322 because of this virus - that's pure BS. There is much to be hopeful for within the next two years when Phase III will be...

Your statement in and of itself is absolutely true and there are physicians you may find who will just sign off on it with or without insurance. However, many if not most primary care physicians require that you have health insurance just to get an appointment and then be diagnosed to get the...

You have a good point as it relates to Australia and the same would be true for Canada and Great Britain as well, but I do not think this would be the case in the United States. There will be ENTs nationwide involved in Phase III treating a few thousand participants. These physicians are...